Transcenta Reveals Breakthrough in G/GEJ Cancer Therapy

Transcenta Holding Limited (HK:6628) has released an update.

Transcenta Holding Limited has reported promising results from their first-line triple combination trial of Osemitamab (TST001), Nivolumab, and CAPOX for advanced G/GEJ cancer, showing a median progression-free survival of 14.2 months and a 68% objective response rate in patients with high/medium CLDN18.2 expression and known PD-L1 CPS. The company has noted that these results, presented at ESMO 2024, confirm the synergistic effect of the triple therapy, particularly in patients with low PD-L1 expression. This data suggests a significant improvement in outcomes compared to historical data from other therapies, indicating a potential breakthrough in the treatment of G/GEJ cancer.

For further insights into HK:6628 stock, check out TipRanks’ Stock Analysis page.